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KEY POINTS SUMMARY 32 
 Glucocorticoids regulate fetal and adult glucose metabolism, in part by influencing the 33 
actions of insulin. However, their effects on materno-fetal glucose partitioning remain 34 
largely unknown. 35 
 In this study, when pregnant mice were given the natural glucocorticoid, 36 
corticosterone, plasma insulin concentrations and liver insulin-signalling increased but 37 
blood glucose concentration was normal. 38 
 However, in the placenta, glucose transport was reduced in association with lower 39 
activity of some insulin signalling proteins, depending on the day of pregnancy and 40 
maternal food intake. 41 
 In both liver and placenta, there was increased expression of the Redd1 (Ddit4) gene 42 
when plasma corticosterone was raised. 43 
 The results show that maternal glucocorticoids interact with signalling pathways in the 44 
placenta to limit materno-fetal glucose partitioning.  45 
ABSTRACT 46 
Glucocorticoids affect glucose metabolism in adults and fetuses, but their effects on materno-47 
fetal glucose partitioning remain unknown. This study measured maternal hepatic glucose 48 
handling and placental glucose transport together with insulin signalling in these tissues in 49 
mice drinking corticosterone either from day (D) 11 to D16 or D14 to D19 of pregnancy 50 
(term=D21). On the final day of administration, corticosterone-treated mice were 51 
hyperinsulinaemic (P<0.05) but normoglycaemic compared to untreated controls. In maternal 52 
liver, there was no change in glycogen content or glucose-6-phosphatase activity but 53 
increased Slc2a2 glucose transporter expression in corticosterone-treated mice, on D16 only 54 
(P<0.05). On D19, but not D16, transplacental 
3
H-methyl-D-glucose clearance was reduced 55 
by 33% in corticosterone-treated dams (P<0.05). However, when corticosterone-treated 56 
animals were pair-fed to control intake, to prevent the corticosterone-induced increase in food 57 
consumption, 
3
H-methyl-D-glucose clearance was similar to the controls. Depending upon 58 
gestational age, corticosterone treatment increased phosphorylation of the insulin-signalling 59 
proteins Akt and glycogen synthase-kinase 3β in maternal liver (P<0.05) but not placenta 60 
(P>0.05). Insulin receptor and insulin-like growth factor type I receptor abundance did not 61 
differ with treatment in either tissue. Corticosterone upregulated the stress-inducible 62 
mechanistic target of rapamycin (mTOR) suppressor, Redd1 in liver (D16 and D19) and 63 
placenta (D19), in ad libitum fed animals (P<0.05). Concomitantly, hepatic protein content 64 
and placental weight were reduced on D19 (P<0.05), in association with altered abundance 65 
and/or phosphorylation of signalling proteins downstream of mTOR. Taken together, the data 66 
indicate that maternal glucocorticoid excess reduces fetal growth partially by altering 67 
placental glucose transport and mTOR signalling. 68 
 69 
ABBREVIATIONS 70 
4E-BP1, eukaryotic translation initiation factor 4E binding protein 1; D, day of pregnancy; 71 
GLUT, glucose transporter; GSK-3β, glycogen synthase kinase 3β; IGF1R, insulin-like 72 
growth factor type I receptor; IR, insulin receptor; mTOR, mechanistic target of rapamycin; 73 
p70 S6 kinase, p70 ribosomal protein S6 kinase; PF, pair-fed  74 
INTRODUCTION 75 
Glucocorticoids have an important role in regulating metabolism in adult animals (McMahon 76 
et al., 1988). Glucocorticoids in the fetal circulation also affect fetal glucose metabolism, 77 
particularly glycogen deposition and mobilization in fetal tissues during late gestation 78 
(Fowden & Forhead, 2011). However, whether maternal glucocorticoid concentrations 79 
influence the materno-fetal supply of glucose remains unknown.  Glucose is supplied to the 80 
fetus by facilitated diffusion across the placenta, down the materno-fetal glucose 81 
concentration gradient (Battaglia & Meschia, 1988). As the glucose requirement of the 82 
growing fetus increases through pregnancy, alterations in the gradient and placental transport 83 
capacity ensure that the glucose supply meets this demand (Molina et al., 1991; Sakata et al., 84 
1995; Yamaguchi et al., 1996; Ehrhardt & Bell, 1997). Glucocorticoids are well placed to 85 
influence materno-fetal glucose supply as their bioavailability changes throughout pregnancy 86 
with increasing maternal and fetal adrenal secretion and tissue-specific changes in activity of 87 
the 11β hydroxysteroid dehydrogenases, which increase (type I) or decrease (type II) the local 88 
availability of active glucocorticoids (Barlow et al., 1974; Condon et al., 1997) Moreover, 89 
maternal glucorticoid availability rises in response to environmental stressors that alter 90 
growth in utero, including excess light and/or heat, physical restraint, infection and dietary 91 
restriction of calories and protein (Ward & Weisz, 1984; Montano et al., 1991; Lesage et al., 92 
2001; Asiaei et al., 2011; Belkacemi et al., 2011; Sferruzzi-Perri et al., 2011; Cottrell et al., 93 
2012). However, whether alterations in materno-fetal glucose partitioning underlie the 94 
reduction in birth weight when maternal glucocorticoids are elevated during pregnancy 95 
(Seckl, 2004) also remains unknown. 96 
 97 
The availability of maternal glucose for transfer to the fetus is maintained, in part, by reduced 98 
peripheral glucose uptake by the maternal tissues and an enhanced rate of glucose production 99 
by the maternal liver, which increases in size during pregnancy (Mottola & Christopher, 100 
1991; Nolan & Proietto, 1996; Saad et al., 1997; Bustamante et al., 2010). In the liver, 101 
glycogenolysis and gluconeogenesis produce glucose, which is released into the circulation 102 
via the high-capacity glucose transporter GLUT2, encoded by the Slc2a2 gene. In turn, 103 
glucose crosses the placenta by facilitated diffusion, primarily via the transporters GLUT1 104 
(Slc2a1) and GLUT3 (Slc2a3), although as many as five isoforms have been identified in the 105 
mammalian placenta (Zhou & Bondy, 1993; Limesand et al., 2004; Jones et al., 2013). 106 
GLUT1 is also expressed at low levels in the liver, where it facilitates basal glucose uptake 107 
(Olson & Pessin, 1996). Synthetic glucocorticoids, such as dexamethasone, are known to 108 
increase hepatic glycogen content and activity of the final, rate-limiting glucogenic enzyme, 109 
glucose-6-phosphatase in pregnant rats and sheep (Klepac, 1985; Franko et al., 2007). 110 
Moreover, placental GLUT expression is altered by maternal treatment with synthetic 111 
glucocorticoids in pregnant rats (Hahn et al., 1999; Langdown & Sugden, 2001). Thus, when 112 
glucocorticoid concentrations are raised inappropriately by stress or exogenous 113 
administration, alterations in hepatic release and placental transport of glucose may alter the 114 
fetal supply and thus contribute to fetal growth restriction induced by these hormones. 115 
 116 
Glucocorticoids may affect both the maternal liver and placenta by interacting with the 117 
insulin-signalling pathway.  Insulin can act via either the insulin receptor (IR) or the related 118 
insulin-like growth factor type I receptor (IGF1R). The metabolic effects of activation of 119 
either receptor are mediated by phosphorylation of the serine/threonine kinase Akt 120 
(Taniguchi et al., 2006). In the liver, phosphorylated Akt stimulates glycogen synthesis 121 
through glycogen synthase-kinase 3β (GSK-3β) and inhibits gluconeogenic enzyme 122 
expression. Akt also activates the mechanistic target of rapamycin (mTOR) pathway, which 123 
promotes protein synthesis via phosphorylation of the eukaryotic translation initiation factor 124 
4E binding protein 1 (4E-BP1) and p70 ribosomal protein S6 kinase (p70 S6 kinase). 125 
Dexamethasone enhances the suppressive effect of insulin on hepatic glucose production but 126 
induces peripheral insulin resistance in pregnant rats (Holness & Sugden, 2001). In non 127 
pregnant rats, dexamethasone also impairs insulin receptor signalling in the liver (Saad et al., 128 
1993) and attenuates insulin stimulated phosphorylation of Akt and GSK-3β in skeletal 129 
muscle (Ruzzin et al., 2005). Moreover, dexamethasone inhibits protein synthesis in muscle, 130 
in part by upregulating the mTOR supressor, regulated in development and DNA-damage 131 
responses 1 (Redd1, also known as Ddit4) (Wang et al., 2006; McGhee et al., 2009; Britto et 132 
al., 2014). 133 
 134 
Whilst both IR and IGF1R are present in the placenta in rodents and other species (Posner, 135 
1974), transplacental glucose transport is not directly insulin-sensitive, as GLUT4 is not 136 
expressed in the trophoblast (Hay, 2006). However, the mitogenic, anti-apoptotic and 137 
anabolic actions of the insulin signalling cascade may indirectly influence the fetal nutrient 138 
supply by influencing cellular proliferation or transporter protein abundance in the placenta 139 
(Mandl et al., 2002; Jansson et al., 2003). Certainly, the expression and phosphorylation level 140 
of insulin-receptor-Akt signalling proteins are reduced in the small placentae of human 141 
infants with intrauterine growth restriction (Laviola et al., 2005; Yung et al., 2008). 142 
Moreover, when placental growth restriction is induced by dexamethasone administration in 143 
rats or dietary manipulations in larger animals, phosphorylation of Akt and of proteins of the 144 
mTOR pathway is decreased, in association with a reduction in glucose transporter protein on 145 
the trophoblast membrane (Ain et al., 2005; Rosario et al., 2011; Kavitha et al., 2014).  146 
 147 
The aim of this study was to determine whether elevated maternal concentrations of the 148 
natural glucocorticoid, corticosterone, influence hepatic glucose handling and the materno-149 
fetal glucose supply in the pregnant mouse. Mice were given exogenous corticosterone at a 150 
dose designed to produce plasma corticosterone concentrations similar to those reported 151 
previously in undernourished or light/heat stressed dams (Montano et al., 1991; Sferruzzi-152 
Perri et al., 2011) . One group of animals was given corticosterone from day (D)11, when the 153 
definitive placenta is established, to D16, when it attains its maximum weight (term is D21) 154 
(Coan et al., 2004). A second group was given corticosterone between day D14 and D19 of 155 
pregnancy, the period characterised by most rapid absolute growth of the fetus. We 156 
specifically hypothesized that corticosterone would alter the capacity of the liver to release 157 
glucose and the capacity of the placenta to transport it to the fetus. Moreover, we determined 158 
whether these changes were associated with alterations in insulin-signalling within the 159 
tissues.  160 
MATERIALS AND METHODS 161 
Animals 162 
All procedures were conducted under the Animals (Scientific Procedures) Act 1986. 163 
C57BL6/J mice were group housed, in 12 hr:12 hr light:dark conditions with ad libitum 164 
access to water and standard chow (Rat and Mouse Number 3 Breeding, Special Diet 165 
Services). Female mice (6-8 weeks old) were mated overnight with stud males and the day of 166 
copulatory plug detection designated day (D) 1 of pregnancy. As described in detail 167 
previously (Vaughan et al., 2012), pregnant females were randomly allocated to receive 168 
corticosterone treatment (corticosterone 21-hemisuccinate, Q1562-000, Steraloids Inc, 169 
Newport, RI, USA; 200 µg ml
-1
 in drinking water) either from D11 to D16 (n=20) or from 170 
D14 to D19 (n=31) (Fig. 1). Mean corticosterone dose was 83 ± 9 µg g
-1
 day
-1
 in dams treated 171 
from D11 to D16 and 81 ± 6 µg g
-1
 day
-1 
in those treated later in pregnancy. Controls (n=74) 172 
drank tap water throughout. Daily ad libitum food intake per mouse was significantly greater 173 
than control values during corticosterone treatment from D14 to D19 (5.2 ± 0.1 g day
-1
, n=4 174 
cages; controls 4.3 ± 0.1 g day
-1
, n=8 cages, P<0.05), but not D11 to D16 (4.3 ± 0.1 g day
-1
, 175 
n=6 cages; controls 4.1 ± 0.2 g day
-1
, n=15 cages) (Vaughan et al., 2012). Consequently, a 176 
subset of animals (n=14) were corticosterone treated and limited to the average food intake of 177 
control mice between D14 and D19. Mice were studied on D16 or D19, according to the 178 
methods detailed below. 179 
 180 
Materno-fetal 
3
H-methyl-D-glucose clearance and tissue collection 181 
On the study day, all mice were anaesthetized with an intraperitoneal injection of fentanyl-182 
fluanisone and midazolam in water (1:1:2, 10 µg ml-1, Janssen Animal Health, High 183 
Wycombe, UK). In a subset of animals (n=41), unidirectional materno-fetal clearance of the 184 
non-metabolisable analogue, 
3
H-methyl-D-glucose (MeG, NET379001MC, specific activity 185 
2.22 TBq mmol
-1
) was measured at both ages using previously described techniques (Sibley 186 
et al., 2004). In all mice, a blood sample was taken from the heart into a chilled, EDTA-187 
coated tube. The mouse was then killed by cervical dislocation and weighed before and after 188 
removal of the uterus. The maternal liver and individual placentae were dissected out, 189 
weighed and flash frozen in liquid nitrogen. Blood samples were centrifuged and the 190 
separated plasma stored at -20°C. In animals given MeG, the time (<4 min) from injection of 191 
the tracer to collection of the blood sample was recorded and MeG content was measured in 192 
maternal plasma and in whole fetuses digested in Biosol (National Diagnostics, Hull, UK) 193 
using liquid scintillation counting (Optiphase Hisafe and LKB Wallac 1216 Rackbeta, both 194 
Perkin Elmer, Cambridge, UK).  195 
Blood glucose and plasma hormone measurements 196 
Glucose concentration was measured in whole blood at the time of collection using a hand-197 
held glucometer (One-Touch, Orthoclinical Diagnostics, High Wycombe, UK). 198 
Corticosterone, insulin, and insulin-like growth factor I (IGF-I) concentrations were 199 
measured in EDTA-plasma. 200 
Corticosterone was measured using a commercially available radioimmunoassay (#07-201 
120102, MP Biomedicals, Orangeburg, NY, USA) as described previously (Vaughan et al., 202 
2012). Intra-assay and interassay coefficients of variation for three pools of quality controls 203 
were 7.3% (mean 193.9 ng ml
-1
) and 6.9% (mean 248.7 ng nl
-1
), respectively, and the lower 204 
detection limit of the assay was 7.7 ng ml
-1
. Rodent-specific enzyme-linked immunosorbent 205 
assays (ELISA) were used to measure insulin (Crystal Chem Inc, Downers Grove, IL, USA) 206 
and IGF-I (R&D Systems Europe Ltd, Abingdon, UK). In all cases, intra-assay coefficient of 207 
variation was less than 7%. The limits of detection of the assays were 0.1 ng ml
-1
 for insulin 208 
and 3.5 pg ml
-1
 for IGF-I. 209 
 210 
Glycogen and protein content, and glucose-6-phosphatase activity 211 
Glycogen content and glucose-6-phosphatase activity were determined per gram of maternal 212 
liver (n=5-8 per treatment group), as described previously (Franko et al., 2007). Briefly, for 213 
the determination of glycogen, liver homogenates in ice-cold water (0.1ml of 100 mg/ml 214 
homogenate, in duplicate) were incubated with amyloglucosidase (70U) for 10 minutes. 215 
Subsequently, the reaction mixture was deproteinised (zinc sulphate and barium hydroxide) 216 
and centrifuged before glucose concentration was measured in the supernatant using a Yellow 217 
Springs glucose analyser (2300 Statplus) (Franko et al., 2007). For the determination of 218 
glucose-6-phosphatase activity, homogenates made in 250 µM sucrose solution (0.1ml of 10 219 
mg/ml homogenate) were incubated with glucose-6-phosphate (25 µM) for 10 minutes. The 220 
reaction was stopped by the addition of trichloracetic acid-ascorbic acid solution and then 221 
centrifuged. Inorganic phosphate was determined colorimetrically in the supernatant through 222 
the addition of ammonium molybdate, in the presence of arsenite-citrate reagent (Fowden et 223 
al., 1993). For both assays, non-enzymatic production of glucose or phosphate was 224 
determined for each homogenate and subtracted from the enzymatic production. Liver and 225 
placenta protein content was determined using the Lowry assay (Forhead et al., 2003). 226 
 227 
Signalling protein abundance and phosphorylation 228 
Western blotting was used to determine the total abundance and phosphorylation level of 229 
signalling proteins both in maternal liver and placentae (n=5-9 per group, one placenta per 230 
litter). Protein extracts were resolved by electrophoresis and transferred to a nitrocellulose 231 
membrane for interrogation. Equal protein loading was verified by Ponceau staining 232 
(Romero-Calvo et al., 2010). Antibodies to the following targets were used: insulin receptor 233 
β, IGF-I receptor β (both 1:400 dilution, from Santa Cruz Biotechnology, Inc. Dallas, TX, 234 
USA), Akt total and phosphorylated (Ser473), glycogen synthase kinase 3β total and 235 
phosphorylated (Ser21/9), 4E-binding protein total and phosphorylated (Thr37/46), and p70 236 
S6 kinase total and phosphorylated (Thr389) (all 1:1000 dilution, from Cell Signalling 237 
Technology, Danvers, MA, USA). The intensity of antibody binding was visualised using the 238 
enhanced chemiluminescence reaction (Amersham) and quantified with Image J. 239 
Gene expression 240 
Quantitative real time PCR was used to measure gene expression in maternal liver and in the 241 
placenta second closest in weight to the mean of each litter (n=6 per treatment, per age).  242 
Expression of Slc2a1 (Taqman gene expression assay Mm00441473_m1). Slc2a2 243 
(Mm00446229_m1), Slc2a3 (Mm00441483_m1), Nr3c1 (Mm00433832_m1), Hsd1 244 
(Mm00476182_m1), Hsd2 (Mm01251104_m1), Redd1 (Mm00512504_g1), Vegf 245 
(Mm01281449_m1), Igf2 (Mm00439564_m1) and the placental specific Igf2P0 transcript 246 
(primer and probe sequences in (Coan et al., 2010)) were normalised to the geometric mean 247 
of Hprt1 (Mm00446968_m1) and Sdha (Mm01352366_m1) using the ΔΔCt method (all 248 
Taqman assays from Applied Biosystems, Warrington, UK using the 7500 Fast System). 249 
 250 
Statistics 251 
All data are presented as mean ± SEM. Separate statistical comparisons were made at D16 252 
and D19. Results were considered significant when P<0.05. At D16, the control group and 253 
corticosterone treated group were compared by unpaired Student’s t-test. At D19, the three 254 
groups (control, D11-14 corticosterone, D14-19 corticosterone ad lib and D14-19 255 
corticosterone pair-fed) were compared by one-way ANOVA; when there was an overall 256 
effect of treatment, individual groups were compared pairwise with a Bonferroni post hoc 257 
test. Where measurements were made for individual fetuses within a litter (fetal and placental 258 
weight, MeG clearance), each measurement was considered a replicate so litter means were 259 
calculated such that the number of subjects was the number of litters.   260 
RESULTS 261 
Hormone levels and biometry 262 
Exogenous corticosterone treatment raised plasma corticosterone concentrations, as reported 263 
previously (Table 1, Vaughan et al, 2012). However, when corticosterone treated dams were 264 
pair-fed to control food intake, the rise in plasma corticosterone was smaller than in ad 265 
libitum fed dams and did not differ significantly from control values. Plasma insulin was also 266 
elevated by corticosterone treatment over either age range, irrespective of food intake, but 267 
blood glucose concentration did not differ between treatment groups (Table 1). Maternal 268 
plasma IGF-I concentration was unaffected by corticosterone treatment at D16 and D19 269 
(Table 1). 270 
Corticosterone treatment from D11 to D16 reduced the weight of the pregnant mouse on D16 271 
(Table 2). Specifically, the gravid uterus was lighter in corticosterone-treated animals 272 
whereas maternal carcass weight did not differ significantly, compared to controls (Table 2). 273 
When corticosterone was given from D14 to D19, there was no effect of treatment on either 274 
total body weight, uterus weight or carcass weight on D19, even when corticosterone treated 275 
mice were pair-fed to controls (Table 2). However, when weights were expressed as a 276 
percentage of whole body weight, there was an overall increase in the percentage weight of 277 
maternal carcass and decrease in percentage weight of the uterus following corticosterone 278 
administration at both D16 and D19 (Table 2). 279 
Corticosterone reduced fetal weight by 8% and 19% at D16 and D19, respectively (Table 2). 280 
Placental weight was also reduced by corticosterone treatment at both ages, regardless of 281 
maternal food intake (Table 2). The number of viable fetuses per litter was unaffected by 282 
maternal treatment (Table 2). 283 
Maternal liver 284 
Glucogenic capacity 285 
Following corticosterone administration from D11 to D16, the maternal liver was lighter as a 286 
percentage of carcass weight, although not as an absolute value compared to controls (Table 287 
3). At D19, neither absolute nor percentage liver weight was affected by corticosterone 288 
treatment. Neither hepatic glycogen content nor glucose-6-phosphatase activity were affected 289 
by treatment at either age. However, there was a significant decrease in hepatic protein 290 
content in D14-19 corticosterone-treated, pair fed animals, relative to those receiving 291 
corticosterone and eating ad libitum (Table 3). 292 
Gene expression 293 
Hepatic Slc2a1 glucose transporter expression was significantly lower than controls in 294 
animals given corticosterone from D14 to D19 but not from D11 to D16 (Fig 2). Conversely, 295 
Slc2a2 expression was significantly elevated in animals given corticosterone from D11 to 296 
D16 but not from D14 to D19 (Fig. 2). Abundance of the Nr3c1 glucocorticoid receptor in the 297 
liver of the pregnant mouse was reduced by glucocorticoid treatment at both gestational ages 298 
(Fig. 2). Furthermore, corticosterone-treated animals had a significantly lower hepatic 299 
expression of the glucocorticoid-activating Hsd1 gene, compared to controls, at D16 but not 300 
at D19. Hsd2 abundance was too low to quantify accurately in liver tissue. Hepatic 301 
expression of the Redd1 gene was increased ~4-fold in ad libitum fed, corticosterone-treated 302 
dams at both D16 and D19 but was not different from controls in corticosterone treated, pair-303 
fed animals at D19 (Fig. 2). 304 
Signalling protein abundance and phosphorylation 305 
Corticosterone treatment did not significantly alter hepatic expression of the insulin receptor 306 
β or the insulin-like growth factor type I receptor β, compared to controls at either age (Fig. 307 
3). Downstream of the receptors, total Akt but not serine-473 phosphorylated Akt was 308 
reduced by corticosterone treatment at D16 (Fig. 3). In contrast, phosphorylated but not total 309 
Akt was increased in the corticosterone-treated, pair-fed group. The ratio of phospho to total 310 
Akt was increased in all corticosterone treated groups, irrespective of age or food intake 311 
during treatment. Serine-9/21 phosphorylated GSK-3β was also increased during 312 
corticosterone treatment at both ages, regardless of maternal food intake. Total GSK-3β 313 
abundance was affected by treatment on D19 only, when it was higher in the corticosterone-314 
treated, ad libitum fed group than in either the corticosterone-treated, pair-fed animals or the 315 
untreated controls. Although neither total nor phosphorylated 4E-BP1 were affected by 316 
corticosterone, there was a significant effect of treatment on the phosphorylation of p70 S6 317 
kinase at threonine-389 on D19, which was again highest in the D14 to D19 treated, ad 318 
libitum fed group. 319 
Placenta 320 
Materno-fetal MeG clearance 321 
There was an overall effect of treatment on transplacental methyl-D-glucose clearance at D19 322 
(P=0.04), but not D16 (P>0.05, Fig. 4). Compared to D19 controls, both materno-fetal 323 
clearance and fetal accumulation of the tracer was lower in those mice given corticosterone 324 
from D14 to D19 (Fig. 4). However, limiting food intake to control levels in corticosterone-325 
treated dams abolished the effect on placental glucose transport at D19. 326 
Gene expression 327 
Placental expression of both glucose transporter genes, Slc2a1 and Slc2a3 was increased in 328 
corticosterone treated mice on D16 (Fig. 5). However, on D19 Slc2a1 and Slc2a3 expression 329 
was similar in all groups. Conversely, placental Redd1 expression was increased in ad libitum 330 
fed, corticosterone treated dams on D19 but not D16. Pair-feeding corticosterone-treated 331 
dams between D14 and D19 limited the increase in Redd1 expression in the placenta such 332 
that there was no significant difference from control values (Fig. 5).  The growth factor Vegf 333 
was more highly expressed in the placenta after corticosterone treatment only on D19. There 334 
was no change in Igf2 or Igf2P0 expression with corticosterone treatment at either age (Fig. 335 
5). Moreover, there was no significant difference in placental expression of Nr3c1, Hsd1 and 336 
Hsd2 between control and corticosterone-treated animals, as reported previously (Vaughan et 337 
al., 2012).  338 
Signalling protein abundance and phosphorylation 339 
Placental insulin receptor and IGF-I receptor expression levels did not differ with maternal 340 
treatment at either D16 or D19 (Fig. 6). On D16 corticosterone significantly reduced 341 
phosphorylation of Akt at the serine-473 residue, although total protein abundance was 342 
similar to controls. Total Akt abundance was lower in corticosterone-treated, pair-fed animals 343 
in particular compared to controls at D19, but the phospho form was not affected by 344 
treatment. Neither total expression nor phosphorylation of GSK-3β in the placenta was 345 
altered by corticosterone at either age (Fig. 6). There was no change in abundance or 346 
phosphorylation of 4E-BP1 or p70 S6 kinase at D16. However, on D19 there was a tendency 347 
for corticosterone treatment to increase total 4E-BP1 abundance, irrespective of food intake, 348 
without affecting abundance of the threonine-37/46 phosphorylated form. Consequently, 349 
there was a significant decrease in the phospho-4E-BP1:total 4E-BP1 ratio on D19 (P=0.048, 350 
Fig. 6C). At this age, corticosterone also caused a decrease in threonine-389 phosphorylation 351 
of p70 S6 kinase relative to controls, when expressed as a ratio to the total abundance of the 352 
protein. Total protein content per g placenta did not differ significantly between treatment 353 
groups at D16 (control 70 ± 4 mg/g, corticosterone 57 ± 5 mg/g, P=0.085) or D19 (control 67 354 
± 12 mg/g, corticosterone, ad libitum fed 64 ± 5 mg/g, corticosterone, pair-fed, 63 ± 7 mg/g, 355 
P>0.1).  356 
DISCUSSION 357 
This study is the first to demonstrate that in vivo placental glucose transport is reduced in 358 
mice given exogenous corticosterone in late pregnancy. Plasma insulin concentration and 359 
hepatic insulin signalling were elevated in corticosterone treated dams but there was no effect 360 
on maternal hepatic glucogenic capacity or blood glucose concentration. Contrastingly, 361 
depending upon the timing of corticosterone administration, there were alterations in 362 
placental Akt-mTOR signalling consistent with reduced protein synthesis and the observed 363 
placental growth restriction. Although the precise physiological changes in the mother and 364 
placenta depended upon maternal food intake, ultimately maternal glucocorticoid excess led 365 
to a reduction in feto-placental growth. 366 
When pregnant mice were given exogenous corticosterone in their drinking water, plasma 367 
corticosterone concentrations were significantly higher in dams fed ad libitum compared to 368 
those restricted to control food intake, even though the total amount of corticosterone drunk 369 
was the same (Vaughan et al., 2012). With reduced food availability, the noctural period of 370 
food and water intake may have finished earlier in the night in pair-fed dams, allowing more 371 
time for exogenous corticosterone to be cleared from the plasma before measurements were 372 
made at a fixed time the following morning. Certainly, previous studies in rats have shown 373 
that limiting food availability alters the normal circadian rhythm of endogenous 374 
corticosterone secretion (Gallo & Weinberg, 1981). In contrast, maternal plasma insulin 375 
concentration was increased independently of the increase in food intake. This indicates that 376 
oral corticosterone administration had a physiological effect in corticosterone-treated, pair-377 
fed dams even though their plasma corticosterone concentrations were similar to controls on 378 
the study day. Plasma insulin levels are also raised when the synthetic glucocorticoid, 379 
dexamethasone, is given to pregnant rats (Holness & Sugden, 2001) or pregnant women 380 
(Ahmad et al., 2006). Furthermore, dexamethasone raises plasma insulin concentration when 381 
given to non-pregnant rats by intravenous infusion (Saad et al., 1993) but causes hyperphagia 382 
only when infused centrally (Zakrzewska et al., 1999). This suggests that mice treated with 383 
corticosterone in the present study were hyperinsulinaemic as a consequence of peripheral 384 
insulin resistance rather than due to greater nutrient intake. Although maternal corticosterone 385 
did not affect blood glucose concentration in the present study, measurements here were 386 
made in the fed state; thus absorption of glucose from the gut may have obscured changes in 387 
endogenous production or clearance. Indeed, previous studies have shown hyperglycaemia in 388 
fasted (Holness & Sugden, 2001) but not fed (Franko et al., 2010), dexamethasone-treated 389 
pregnant rats. Whilst the natural state of insulin resistance in late pregnancy favours 390 
distribution of resources to the gravid uterus, corticosterone-treated dams exhibited a 391 
preferential decrease in weight of the uterus and contents, rather than of maternal tissues.  In 392 
part, this may be attributable to direct inhibition of fetal growth by corticosterone crossing the 393 
placenta (Fowden et al., 1996) but may also be due to the decreased placental transport of 394 
glucose, seen in this study, and of amino acids, observed previously (Vaughan et al., 2012). 395 
Oral corticosterone treatment did not alter liver glycogen content or G6pase activity, in 396 
contrast to previous studies in pregnant animals using the synthetic glucocorticoid, 397 
dexamethasone (Klepac, 1985; Franko et al., 2007). Downregulation of both the 398 
glucocorticoid receptor (Nr3c1) and the glucocorticoid-activating isoform of 11β-399 
hydroxysteroid dehydrogenase (Hsd1) may mean that local corticosterone bioactivity was not 400 
elevated sufficiently to alter liver enzyme expression, in the present study. Alternatively, the 401 
net effect on hepatic carbohydrate metabolism may have been due to the balance of elevated 402 
plasma corticosterone and increased insulin signalling. In contrast to the effect of 403 
glucocorticoid treatment in the non-pregnant rat (Saad et al., 1993), there was no 404 
downregulation of hepatic IR or IGF1R expression here. Indeed, the phosphorylation state of 405 
signalling proteins downstream of the insulin receptor broadly reflected a normal response to 406 
elevated insulin. Both Akt and GSK-3β were hyperphosphorylated during corticosterone 407 
treatment, which would be expected to suppress gluconeogenic enzyme expression. 408 
Nonetheless, corticosterone treatment did increase hepatic Slc2a2 glucose transporter gene 409 
expression on D16. Slc2a2 gene expression is linked to glucose availability in cultured 410 
hepatocytes (Rencurel et al., 1996) and known to be transcriptionally regulated by other 411 
hormones in vivo (Weinstein et al., 1994). Whilst corticosterone treatment also tended to 412 
decrease hepatic Slc2a1 expression, the transport capacity and absolute abundance of GLUT1 413 
is low in the liver (Olson & Pessin, 1996), meaning it is unlikely to influence glucose release. 414 
Although insulin signalling was not measured in other maternal tissues in the current study, 415 
previous investigations have consistently shown that glucocorticoid treatment impairs 416 
skeletal muscle insulin sensitivity and peripheral glucose uptake in pregnant and non-417 
pregnant rodents, independently of glucose transporter abundance (Haber & Weinstein, 1992; 418 
Holness & Sugden, 2001). Thus, adaptations in both the liver and extra-hepatic tissues tend to 419 
increase glucose availability for transfer to the fetus and are unlikely to contribute to reduced 420 
fetal growth when maternal glucocorticoids are raised. 421 
 422 
Certainly, corticosterone had an effect on hepatic protein content, which was specifically 423 
reduced in the livers of corticosterone-treated, pair fed animals. Although this may be a direct 424 
catabolic effect of corticosterone, reduced phosphorylation of p70 S6 kinase suggests that 425 
there may also be a reduction in mTOR-stimulated protein translation in the livers of these 426 
mice. Paradoxically, expression of the mTOR suppressor Redd1 was increased only in the 427 
livers of ad libitum fed, not pair fed, corticosterone-treated mice, which did not show any 428 
evidence of reduced protein content. The mechanism of altered hepatic protein content may 429 
therefore be more complex in pair-fed animals, when food intake is not increased to balance 430 
the catabolic effect of the glucocorticoid. 431 
 432 
The reduction in materno-fetal glucose clearance in D19 pregnant mice given corticosterone 433 
is in agreement with previous in vivo studies in sheep showing that steady state fetal glucose 434 
uptake is reduced when fetal cortisol concentration is increased (Ward et al., 2004). In 435 
contrast, when pregnant rats are given dexamethasone for two days near term, there is no 436 
change in uterine uptake of a non-metabolisable glucose tracer (Norris et al., 2011), perhaps 437 
reflecting the differing effects of the natural and synthetic glucocorticoids, or the more 438 
prolonged period of glucocorticoid administration in the present study.  Mouse dams given 439 
corticosterone and pair-fed to control food intake did not exhibit a reduction in placental 440 
glucose transport, even though fetal weight was reduced to the same extent as in ad libitum 441 
feeding animals. In part, the apparent interaction between corticosterone and dietary 442 
restriction in influencing materno-fetal glucose clearance in pair-fed dams may relate to their 443 
lower prevailing plasma corticosterone but may also reflect an independent influence of 444 
nutrition on placental glucose transporter abundance, as changes in placental capacity for 445 
glucose transport have been demonstrated previously in pregnant mice and rats fed less than 446 
the normal caloric intake (Lesage et al., 2002; Coan et al., 2010). Fetal growth restriction in 447 
the corticosterone-treated, pair fed animals may have been due to reduced amino acid supply, 448 
as placental methylaminoisobutyric acid clearance is known to be decreased in the 449 
corticosterone-treated mice, irrespective of food intake (Vaughan et al., 2012). Indeed, 450 
previous observations show that natural variations in fetal weight are more closely related to 451 
placental transport of amino acids than glucose at D19 (Coan et al., 2008). Moreover, 452 
although glucose transport capacity per gram of placenta was not affected in the pair-fed 453 
animals, reduced absolute placental weight and vascularity are likely to have impaired net 454 
fetal glucose uptake. The reduced size of the corticosterone-treated placenta may be 455 
explained, in part, by lower abundance or activity of the Akt protein at both D16 and D19. 456 
Akt expression is also reduced in rat placentae growth restricted by maternal dexamethasone 457 
administration (Ain, 2005), although this was accompanied by reduced Igf2 expression, 458 
unlike the present study. Unlike previous studies in dexamethasone-treated rats rats (Hewitt 459 
et al., 2006), placental Vegf expression was increased by corticosterone, suggesting that there 460 
may be an attempt to compensate for the reduction in blood vessel density reported 461 
previously in these mice (Vaughan et al., 2012). The more marked direct effect of 462 
corticosterone on D19 than D16 placentae may reflect the lower placental expression of the 463 
glucorticoid metabolising isoform of 11β-hydroxysteroid dehydrogenase (Hsd2) in later 464 
pregnancy (Condon et al., 1997). 465 
 466 
The observed changes in materno-fetal MeG clearance in corticosterone-treated dams at D19 467 
were not related to placental expression of the glucose transporter genes, Slc2a1 and Slc2a3, 468 
which did not differ with treatment at this age. On the other hand, Slc2a1 and Slc2a3 were 469 
upregulated by corticosterone treatment on D16, without a change in MeG clearance. These 470 
adaptations in placental glucose transport may also relate to changes in expression of glucose 471 
transporter genes Slc2a8 and Slc2a9, which have been shown recently to be regulated by 472 
endocrine signals in the mouse placenta (Jones et al., 2013).  However, post-transcriptional 473 
mechanisms may also have a role in regulating placental nutrient transport when 474 
glucocorticoids are raised. Certainly, adaptations in placental System A amino acid transport 475 
capacity have previously been shown to be temporally dissociated from Slc38a amino acid 476 
transporter expression in corticosterone treated mice (Vaughan et al., 2012). In the present 477 
study, placental glucose transport capacity was specifically reduced when maternal plasma 478 
corticosterone concentration and placental Redd1 expression were raised in the ad libitum 479 
fed, corticosterone treated mice. In pair-fed, corticosterone treated dams, when plasma 480 
corticosterone and placental Redd1 expression were similar to controls, MeG clearance was 481 
not decreased even though the alterations in maternal insulin signalling and feto-placental 482 
growth suggested that these dams had received a physiologically effective dose of 483 
corticosterone. Thus, placental Redd1 expression was closely related to both the prevailing 484 
maternal corticosterone concentration and glucose transport across the placenta. 485 
 486 
In contrast to the current findings, corticosterone reduces placental amino acid transport in 487 
both ad libitum and pair fed dams (Vaughan et al., 2012). Corticosterone, therefore, appears 488 
to affect placental transport of glucose and amino acids by different mechanisms. Since the 489 
ratio of phosphorylated to total 4E-BP1 and p70 S6 kinase abundance was reduced in 490 
corticosterone-treated placentae irrespective of food intake in the current study, placental 491 
amino acid transport appears to be more directly related to inhibition of mTOR than placental 492 
glucose transport. Certainly, 4E-BP1 and p70 S6 kinase hypophosphorylation is associated 493 
with reduced amino acid transporter protein expression in the placentae of rat dams deprived 494 
of protein during pregnancy (Rosario et al., 2011).   Collectively, these observations suggest 495 
that corticosterone reduces placental glucose transport via Redd1 independently of mTOR 496 
while it acts to lower placental amino acid transport by inhibition of mTOR dependent 497 
translation or translocation of transporters to the cell membrane. Indeed, the placental 498 
adaptation in signalling downstream of mTOR induced by corticosterone overexposure may 499 
be indirect and mediated by the maternal hyperinsulinaemia observed in both the ad libitum 500 
fed and pair-fed groups of dams. The precise effects of corticosterone on placental nutrient 501 
transport, therefore, depend on both its actual circulating concentration and its longer term 502 
actions on maternal metabolism and other metabolic hormone concentrations. Fetal sex may 503 
also be an important factor in determining the effect of maternal corticosterone on materno-504 
fetal nutrient transport, as the normal permeability of the placenta to natural glucocorticoids 505 
is known to differ between male and female conceptuses (Montano et al., 1993). 506 
 507 
Overall, the data show that increased concentrations of natural glucocorticoids in the 508 
pregnant mother may limit materno-fetal glucose partitioning and thus fetal growth by 509 
reducing placental glucose transport capacity. Moreover, whilst natural glucocorticoids 510 
increase insulin signalling and glucose transporter expression in the maternal liver, they 511 
impair insulin signalling in the placenta with possible consequences for the activity of other 512 
nutrient transport systems. As glucose is the major substrate of fetal growth and oxidative 513 
metabolism, these effects are likely to impact upon the size and metabolic phenotype of the 514 
infant at birth. However, the interaction of glucocorticoids with other nutrient sensing 515 
pathways in the placenta may represent a target for interventions to rescue fetal growth when 516 
maternal glucocorticoids are raised during pregnancy. 517 
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TABLES 
Table 1 Mean ± SEM plasma hormone and blood glucose concentrations in control and corticosterone-treated pregnant mice 
 D16 D19 
 Con Cort D11-16 Con Cort D14-19 Cort D14-19 +PF 
Corticosterone 
   ng ml
-1
 
n=23 
632 ± 60 
n=12 
1142 ± 134* 
n=24 
714 ± 41
a 
n=10 
1143 ± 176
b 
n=9 
810 ± 74
ab 
Insulin 
   ng ml
-1
 
n=7 
1.1 ± 0.3 
n=7 
40.3 ± 5.8*
 
n=12 
1.1 ± 0.3
a 
n=7 
20.6 ± 4.5
b 
n=5 
16.5 ± 8.3
b 
IGF-I 
   ng ml
-1
 
n=6 
208 ± 21 
n=6 
193 ± 12 
n=8 
219 ± 25 
n=5 
155 ± 13 
n=4 
216 ± 10 
Glucose 
   mM 
n=32 
9.7 ± 0.4 
n=18 
10.5 ± 0.7 
n=35 
9.2 ± 0.3 
n=16 
9.5 ± 0.7 
n=14 
10.2 ± 0.6 
Groups were compared by Student’s t-test at D16, * denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at D19, a b denote 
significantly different values by Bonferroni post hoc comparisons (P<0.05). Values in bold indicate significant overall effect of treatment. n 
values are given in table. PF indicates corticosterone-treated animals pair-fed to control food intake. 
  
Table 2 Mean ± SEM maternal, fetal and placental biometry in control and corticosterone-treated pregnant mice 
 D16 D19 
 Con Cort D11-16 Con Cort D14-19 Cort D14-19 +PF 
 n=32 n=20 n=42 n=17 n=14 
Body weight g 29.6 ± 0.5 27.8 ± 0.4* 34.6 ± 0.6
 
34.3 ± 1.0
 
32.2 ± 0.9
 
Hysterectomised g 23.2 ± 0.4 22.8 ± 0.4 23.2 ± 0.3
 
24.7 ± 0.7
 
23.1 ± 0.6
 
   % total body weight 78.6 ± 0.6 80.8 ± 0.5* 67.5 ± 0.7
a 
72.1 ± 1.1
b 
71.9 ± 1.1
b 
Uterus g 6.4 ± 0.2 5.3 ± 0.1* 12.2 ± 1.0 9.6 ± 0.5 9.1 ± 0.5 
   % total body weight 21.4 ± 0.6 19.2 ± 0.5* 32.5 ± 0.7
a 
27.9 ± 1.1
b 
28.1 ± 1.1
b 
Fetus mg 390 ± 4 361 ± 5* 1178 ± 11
a 
959 ± 15
b 
937 ± 29
b 
Placenta mg 101 ± 1 95 ± 1* 89 ± 1
a 
78 ± 1
b 
78 ± 1
b 
Number of fetuses 7.0 ± 0.4 6.4 ± 0.2 6.7 ± 0.2 6.9 ± 0.3 6.4 ± 0.4 
Groups were compared by Student’s t-test at D16, * denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at D19, a b denote 
significantly different values by Bonferroni post hoc comparisons (P<0.05). Values in bold indicate significant overall effect of treatment. n 
values are given in table. PF indicates corticosterone-treated animals pair-fed to control food intake. 
  
Table 3 Mean ± SEM liver weight and glucogenic capacity in control and corticosterone-treated pregnant mice 
 D16 D19 
 Con Cort D11-16 Con Cort D14-19 Cort D14-19 +PF 
Liver weight  n=32 n=20 n=37 n=16 n=14 
   mg 1766 ± 42 1641 ± 42 1709 ± 33
 
1788 ± 78
 
1781 ± 53
 
   % of carcass 7.6 ± 0.1 7.1 ± 0.1* 7.4 ± 0.1
 
7.2 ± 0.2
 
7.7 ± 0.3
 
      
Hepatic glucogenic capacity n=6 n=6 n=8 n=7 n=5 
   Glycogen mg/g 45.3 ± 2.8 39.3 ± 4.3 48.6 ± 2.7 43.8 ± 4.1 46.2 ±2.8 
   Glycogen total mg 76.0 ± 6.6 62.4 ± 8.1 80.8 ± 5.9 79.7 ± 8.4 81.3 ± 5.9 
   G-6-Pase U/g 20.9 ± 2.3 26.6 ± 1.0 26.4 ± 0.6
 
25.3 ± 1.3
 
22.8 ± 2.0
 
   G-6-Pase U/mg protein 378 ± 36 406 ± 24 374 ± 27
 
315 ± 14
 
377 ± 46
 
   Protein mg/g 56 ± 5 66 ± 2 73 ± 5
ab 
80 ± 3
a 
62 ± 3
b 
Groups were compared by Student’s t-test at D16, * denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at D19, a b denote 
significantly different values by Bonferroni post hoc comparisons (P<0.05). Values in bold indicate significant overall effect of treatment. n 
values are given in table. PF indicates corticosterone-treated animals pair-fed to control food intake. 
  
FIGURE LEGENDS 
Figure 1 
Flow chart illustrating allocation of mice to different experimental treatments, feeding 
regimens and study days. Grey shading indicates animals given exogenous corticosterone 
(200 µg ml
-1
 in drinking water). D, day of pregnancy. 
 
Figure 2 
Mean ± SEM maternal liver expression of genes involved in glucose transport and 
glucocorticoid action at (A) day 16 and (B) day 19 of pregnancy. Expression determined by 
the ΔΔCt method relative to Groups were compared by Student’s t-test at day 16, * denotes 
P<0.05 vs Con. Groups were compared by one-way ANOVA at day 19, 
a b
 denote 
significantly different values by Bonferroni post hoc comparisons (P<0.05). n=6 per 
treatment group at each age 
 
Figure 3 
Mean ± SEM maternal liver abundance of total and phosphorylated forms of insulin-
signalling proteins. (A) Representative blots from each age and treatment group, approximate 
molecular weights of the protein bands are given to the right of the blot, (B) abundances at 
day 16, (C) abundances at day 19 of pregnancy. Groups were compared by Student’s t-test at 
day 16, * denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at day 19, 
a b
 
denote significantly different values by Bonferroni post hoc comparisons (P<0.05). D16 
control n=6, corticosterone-treated n=7; D19 control n=9, corticosterone-treated ad libitum 
n=8, corticosterone-treated pair-fed n=5. 
 
Figure 4 
Mean ± SEM placental transport of non-metabolisable 
3
H-methyl-D-glucose at day 16 and 
day 19 of pregnancy. (A) Unidirectional materno-fetal clearance per gram of placenta, (B) 
accumulation per gram of fetus.  Groups were significantly different by Student’s t-test at day 
16. Groups were compared by one-way ANOVA at day 19, † indicates overall P<0.05; a b 
denote significantly different values by Bonferroni post hoc comparisons (P<0.05). D16 
control n=7, corticosterone-treated n=5; D19 control n=17, corticosterone-treated ad libitum 
n=7, corticosterone-treated pair-fed n=5. 
 
Figure 5 
Mean ± SEM placental expression of genes involved in glucose transport and glucocorticoid 
action, and growth factors at (A) day 16 and (B) day 19 of pregnancy. Expression determined 
by the ΔΔCt method relative to Groups were compared by Student’s t-test at day 16, * 
denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at day 19, 
a b
 denote 
significantly different values by Bonferroni post hoc comparisons (P<0.05). Nr3c1, Hsd1 and 
Hsd2 expression data have been reported in a previous publication. n=6 per treatment group 
at each age. 
 
Figure 6 
Mean ± SEM placental abundance of total and phosphorylated forms of insulin-signalling 
proteins. (A) Representative blots from each age and treatment group, approximate molecular 
weights of the protein bands are given to the right of the blot, (B) abundances at day 16, (C) 
abundances at day 19 of pregnancy. Groups were compared by Student’s t-test at day 16, * 
denotes P<0.05 vs Con. Groups were compared by one-way ANOVA at day 19, † indicates 
overall P<0.05; 
a b
 denote significantly different values by Bonferroni post hoc comparisons 
(P<0.05). D16 control n=7, corticosterone-treated n=7; D19 control n=6, corticosterone-
treated ad libitum n=6, corticosterone-treated pair-fed n=4. 
 
 
 
 
